Full Text View
Tabular View
No Study Results Posted
Related Studies
Manifestations of Heritable Disorders of Connective Tissue
This study is currently recruiting participants.
Study NCT00270686   Information provided by National Institute on Aging (NIA)
First Received: December 27, 2005   Last Updated: May 28, 2009   History of Changes

December 27, 2005
May 28, 2009
June 2003
December 2012   (final data collection date for primary outcome measure)
 
 
Complete list of historical versions of study NCT00270686 on ClinicalTrials.gov Archive Site
 
 
 
Manifestations of Heritable Disorders of Connective Tissue
Clinical and Molecular Manifestations of Heritable Disorders of Connective Tissue

The purpose of this study is to examine cardiovascular and musculoskeletal complications of heritable connective tissue disorders (HDCT) and the natural history of these complications.

The purpose of this research is to investigate a group of genetic disorders called the Hereditary Disorders of Connective Tissue and describe the health problems associated with these conditions. These disorders and their prominent symptoms include:

  • Marfan Syndrome--vascular dilatation (enlargement) and dissection (a tear in the lining), skeletal abnormalities
  • Ehlers-Danlos Syndrome--soft fragile skin, bleeding problems, joint laxity (looseness), chronic pain
  • Stickler Syndrome--premature osteoarthritis, bifid uvula (a split in the fleshy lobe hanging down from the soft palate), cleft palate, hearing loss, vitreoretinal degeneration (degeneration of the retina and the transparent gel that fills the inner portion of the eyeball between the lens and the retina)

People who have a known or strongly suspected diagnosis are eligible to participate. At the NIA ASTRA unit at Harbor Hospital, a study investigator will obtain a detailed medical history and perform a physical examination on participants. These evaluations will occur every 2 years for 5 years. Additional studies may include an echocardiogram, ECG, Holter study, bone densitometry, blood and urine tests, magnetic resonance imaging (MRI)/MRA studies and vascular studies. A skin biopsy may be done with a separate consent for some participants. Questionnaires about pain and quality of life will be completed by participants.

 
Observational
Cohort, Prospective
  • Ehlers-Danlos Syndrome
  • Marfan Syndrome
  • Stickler Syndrome
 
  • Longitudinal Study Arm: 450 participants who will be involved in extensive testing and will be followed longitudinally. Each participant spends approximately 2 days undergoing clinical evaluations. The clinical visits occur every 1 to 5 years based on the subject's age, medical condition, and ability to travel to the study location.
  • Mutational Analysis Arm: There is an upper limit of 1385 participants for this arm. Participants may come to the NIA Clinical Research Unit for a one-time visit (less than one day in length), or they may enroll off-site by sending in bloods, saliva, or bucca samples for the DNA analysis.
  • Genome Protocol Arm: This arm consists of participants who have been previously enrolled under NHGRI protocol 97-HG-0089, presently inactive. The samples are housed at NIA facilities for use by the PI and collaborators approved by the NIA IRB.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
300
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Established or strongly suspected diagnosis of Ehlers-Danlos, Marfan, or Stickler syndrome within immediate family
  • Personal or family history of one or more of the following features in a pattern suggestive of a heritable connective tissue disorder: Marfanoid body habitus (unusually long limbs and digits, deformation of the chest wall), aortic dilatation and/or dissection (a large vessel that comes out of the heart), aneurysms (balloon shaped enlargements) in other vessels, ectopia lentis (dislocation of the lens of the eye), detached retina (separation of the retina from the eyeball), vitreous degeneration (degeneration of the gel that fills the eye) and/or early onset high myopia (near-sightedness), cleft palate, joint laxity and/or dislocation, premature osteoarthritis, skin fragility, striae (stretch marks), easy bruising, and/or hyperextensible skin, scoliosis (curvature of the spine), spondylolisthesis (slippage of the bones of the spine) and/or dural ectasia (distortion of the lining of the spinal cord), high frequency sensorineural hearing loss (inability to hear certain sounds due to nerve impairment)

Exclusion Criteria:

  • Inability to provide informed consent
  • Pregnant and nursing women may be limited in their participation in some aspects of the study (e.g. ionizing radiation exposure or MRI) during the time that they are pregnant or nursing
Both
12 Years and older
Yes
Contact: NIA Recruiter 410-350-3941 NIAStudiesRecruitmetn@mail.nih.gov
United States
 
NCT00270686
Nazli McDonnell, M.D., Ph.D. Principle Investigator, National Institute of Aging
AG0060
National Institute on Aging (NIA)
 
Principal Investigator: Nazli McDonnell, MD, PhD National Institute on Aging (NIA)
National Institute on Aging (NIA)
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP